USSTOCK.TODAY
Regular Market
Log in Sign up

Viridian Therapeutics Set to Announce Q3 Results: Divergence Between Stock Rise and Earnings Decline

Earnings Whispers · ·by G4L

VRDN
VRDN Viridian Therapeutics Inc
$30.86 +2.22%
View chart & analysis →
  1. 1Viridian Therapeutics is approaching its earnings announcement with a stock price increase of approximately 11.5% since its last report.
  2. 2Wall Street forecasts Q3 revenue of approximately $5.8 million and an expected net loss per share of approximately $1.08.
  3. 3Indicators are expected to worsen with a projected year-over-year decline in Viridian Therapeutics earnings per share (EPS) of approximately 218%.

So what's the key point?

Viridian Therapeutics' stock price has risen, but earnings are expected to decline. Experts anticipate revenue of around $5.8 million and a significant decrease in profits compared to last year.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Viridian Therapeutics beats revenue estimates with Lumvoa launch Earnings Whispers +1 · 6d agoPACCAR beats consensus with $7.937 billion in Q3 revenue Earnings Whispers · Oct 28Vishay Precision Group eyes profitability improvement ahead of Q3 earnings release Earnings Whispers · Oct 28
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news